Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.

doi:10.1016/j.canlet.2024.216608

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.

Cancer letters - 1 Mar 2024

Madorsky Rowdo Florencia P, Xiao Gu, Khramtsova Galina F, Nguyen John, Martini Rachel, Stonaker Brian, Boateng Richard, Oppong Joseph K, Adjei Ernest K, Awuah Baffour, Kyei Ishmael, Aitpillah Frances S, Adinku Michael O, Ankomah Kwasi, Osei-Bonsu Ernest B, Gyan Kofi K, Altorki Nasser K, Cheng Esther, Ginter Paula S, Hoda Syed, Newman Lisa, Elemento Olivier, Olopade Olufunmilayo I, Davis Melissa B, Martin M Laura, Bargonetti Jill

Abstract excerpt

Poly (ADP-ribose) polymerase inhibitors (PARPi) are used for patients with BRCA1/2 mutations, but patients with other mutations may benefit from PARPi treatment. Another mutation that is present in more cancers than BRCA1/2 is mutation to the TP53 gene. In 2D breast cancer cell lines, mutant p53 (mtp53) proteins tightly associate with replicating DNA and Poly (ADP-ribose) polymerase (PARP) protein. Combination...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Genes, p53

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Share to Temozolomide

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 38199587
DOI: 10.1016/j.canlet.2024.216608
PMCID: PMC10922546

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.PMID 38199587Read ↗

Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatmentSemantic proximity Read ↗

Mutant p53 Directs PARP to Regulate Replication Stress and Drive Breast Cancer MetastasisSemantic proximity Read ↗

Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and CisplatinSemantic proximity Read ↗

Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast CancerSemantic proximity Read ↗

Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair.Semantic proximity Read ↗

Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.Semantic proximity Read ↗

The Sensitization of Triple-Negative Breast Cancers to Poly ADP Ribose Polymerase Inhibition Independent of BRCA1/2 Mutation Status by Chemically Modified microRNA-489.Semantic proximity Read ↗

Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer CellsSemantic proximity Read ↗

Analysis of the PARP1, ADP-Ribosylation, and TRIP12 Triad With Markers of Patient Outcome in Human Breast Cancer.Semantic proximity Read ↗

Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging DrugsSemantic proximity Read ↗

Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast CancerSemantic proximity Read ↗

A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.